<DOC>
	<DOCNO>NCT02554955</DOCNO>
	<brief_summary>This study evaluate efficacy safety intravenous daclizumab combination oral mycophenolate mofetil oral sirolimus participant receive heart transplant , risk impair kidney function . The anticipated time study treatment 6 month , target sample size 44 individual .</brief_summary>
	<brief_title>A Study Daclizumab ( Zenapax ) Combination With Mycophenolate Mofetil ( CellCept ) Sirolimus Prevention Acute Rejection Heart Transplant Participants</brief_title>
	<detailed_description />
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Adult participant great 18 year age Single organ ( heart ) transplant recipient At risk posttransplant renal dysfunction Previous organ transplant Previous treatment mycophenolate mofetil , daclizumab sirolimus Positive human immunodeficiency virus ( HIV ) infection History malignancy within last 5 year , except localize treated skin cancer , treat without evident relapse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>